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Abstract
Background: In 2011 there was a strengthening of European Union (EU) legislation on the licencing of herbal
products which, in the UK, resulted in the introduction of the Traditional Herbal Registration (THR) scheme. This
scheme sets out standards for the safety and quality of herbal medicines and includes the provision of information
to the customer on the safe use of the product.
The aim of this study is to replicate a survey undertaken in 2011, prior to the implementation of the THR scheme,
and evaluate the impact of this scheme on the information provided with herbal products bought over-the-counter.
Methods: We undertook a survey on 5 herbal products commonly available over-the-counter (St John’s wort, echinacea,
Ginkgo biloba, Asian ginseng, garlic). The information was searched for key safety messages identified by the National
Center for Complementary and Integrative Health (NCCIH). We also explored the presence of risk of harm information.
Results: We recorded a rise in the number of products registered with the THR scheme (37% in 2016 compared to 7% in
2011). We also identified a reduction in the number of products that did not contain key safety information (75% in 2011
compared to 20% of products obtained in 2016). Risk of harm information was only communicated in
products containing a PIL. We identified more products containing frequency of risk of harm information but
this was not statistically significant.
Conclusion: The introduction of the THR scheme appears to be associated with an increase in the provision
of information about key safety messages on the safe use of herbal products. However, it is important to
note that at least half of the products on the market that are not included in the THR scheme do not
contain any information about their safe use; this includes information about precautions, interactions and
side effects.
The use of NCCIH herbal monographs replicated the methods used in the previous study; we recognise that
the use of a different resource might effect the appraisal of the information provided. We also acknowledge
that surveying presence of information does not assure that the latter is effectively communicated to patients,
for which a close textual analysis would be required. While it is promising that more information is available
after the introduction of the THR scheme, the public needs to be informed about ways to optimise safe use
of all herbal products.
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Background
There is widespread use of herbal medicines across
Europe, America and Australia [1–3]. Herbal products
are commonly available in pharmacies, health food
shops and supermarkets across the UK. For optimal use
of herbal medicines it is important that patients have ac-
cess to information about their safe and effective use,
particularly as the public can perceive herbal medicines
as safe despite documented evidence of precautions, in-
teractions and side effects associated with some products
[4, 5]. Knowledge of these issues is important for con-
sumers to allow them to make informed decisions about
herbal medicines.
However barriers can inhibit the provision of informa-
tion about the safe and effective use to consumers of
herbal medicines. Patients do not always seek informa-
tion from healthcare professionals about herbal products
and do not always disclose their use of them [6]. An
ethnographic study of herbal products retailers in the
USA suggested there can be variable verbal information
provided to consumers at the point of purchase, with
the quality of information provided being unreliable and
dependent on staff training and expertise [7].
A survey of information provided with herbal products
selected from UK pharmacies, supermarkets and health
food shops, undertaken by the authors in 2011, found
that 75% of products did not contain any information
about key issues relevant to safe use [8]. The need for re-
liable information has been identified as a global priority
to enhance the safe and effective use of traditional herbal
medicines, and the WHO Traditional Medicine Strategy
(2014–2023) sets out a number of strategic global objec-
tives designed to promote and regulate their safe and ef-
fective use. Most pertinent are the key objectives which
stipulate the need to promote the safety, efficacy and
quality of traditional medicine (TM) by expanding the
knowledge base, and providing guidance on regulatory
and quality assurance standards [9].
The most significant change in regulatory standards in
the European Union (EU) over recent years has been the
introduction of the European Directive on Traditional
Herbal Medicinal Products (2004/24/EC), which sets the
registration requirements, that should ensure that herbal
medicines meet required standards of quality, safety and
evidence of traditional use prior to being available for
sale [10]. The EU directive aims to harmonise the defin-
ition of traditional herbal medicines across Europe and
sets out requirements for the quality and safety of herbal
medicines to be assessed prior to licensing. The scheme
requires herbal medicines to have a well-documented,
consistent, and longstanding use over at least 30 years
across Europe and should facilitate consumer access to
quality-assured herbal products accompanied with infor-
mation about their quality and safe use [11].
The directive was enacted in 2004, incorporating a 7
year transition period, meaning that the scheme came
into full effect in 2011. By 2011 it was expected that all
herbal medicines should have either a THR or a product
licence. Prior to the introduction of the THR scheme
most available herbal products were ‘unlicensed’ and
changes in licencing represent a swing from a market
that was largely unregulated, to a regulated one [11]. In
our previous study we found that unlicensed products
comprised 93% of the sampled products and that there
was a significant deficit of good quality information pro-
vided on their safe use [12]. It is not clear what the im-
pact of this new scheme has been on the quality of
information provided with herbal products, although in
2010 it was noted that the UK had received large num-
bers of registrations [11].
It has been over 5 years since the introduction of the
new regulations and the impact of the THR scheme on
the information provided with herbal products is not
known. The aim of this study is to replicate the survey
undertaken in 2011 and evaluate the impact of the intro-
duction of the THR scheme on the information provided
with herbal products bought over the counter. Addition-
ally, we also aim to evaluate and compare the extent to
which the information provided with herbal products
communicates the likelihood of risk of harm associated
with herbal medicines and whether this is in line with
recommendations from the UK Medicines and Health-
care products Regulatory Agency (MHRA) and the
European Medicines Agency (EMA).
Methods
Study design
The study used a survey of a sample collected following
same principles as a previous study to undertake a content
analysis of the information provided with five herbal prod-
ucts: St John’s wort, garlic, ginkgo, Asian ginseng (Asian)
and echinacea. We aimed to replicate the methods of the
previous study and these herbal products were collected
in the same way as the sample from 2011. The herbal
products were chosen as they met one or more of the fol-
lowing criteria:
 There is evidence of drug interaction between the
herb and a prescribed medicine [4]
 There exists a published risk-benefit profile on the
herb [5]
 The product is available in retail outlets in local
shopping areas.
We included all varieties of products containing single
herbs i.e. not combined products. The exclusion criteria
included products available as creams, liquids, oils,
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sprays, teas and tinctures. We also excluded combined
herbal products.
Obtaining the products
Products were purchased in 2016 from one UK city. We
purchased all the oral use products containing the five
herbal products available from the following retailers:
1) Two health food stores: one independent health
food store and Holland and Barrett (the UK’s
largest retail chain in this sector)
2) Three pharmacies based in supermarkets (Tesco,
Sainsbury’s and Asda)
3) Three large chain pharmacies (Boots, Superdrug
and Lloyds)
The sample of retailers did not differ significantly from
the 2011 survey, however the independent health store
used in 2011 has since closed and so a replacement store
in the same city was used.
Evaluation criteria
The study aim was to evaluate the information provided
with the herbal products on the completeness and
accuracy in communicating key safety issues about the
product. We used the US National Center for Comple-
mentary and Integrative Health (NCCIH) ‘herbs at a
glance’ monographs as the basis for the development of
the key safety evaluation criteria, in order to ensure
consistency with the methods from the previous survey.
The content of each monograph was searched for key
safety issues on precautions, interactions and side
effects; they were then tabulated resulting in the identifi-
cation of 16 key points for St John’s wort, 7 for Asian
ginseng, 7 for gingko, 6 for garlic and 3 for echinacea.
(Table 1).
In the previous study we identified there was no ‘gold
standard’, authoritative source on herbal medicines and
so we opted to use the US National Centre for Comple-
mentary and Alternative Medicines (NCCAM) herbal
monographs as these covered all of the herbal products
we had purchased. These herbal monographs are
evidence-based resources that provide basic information
about specific herbs. Other resources exist, such as the
EMA - Community Herbal Monographs but these did
not, and do not, contain information about all the sam-
pled herbal products [13]. In 2015 NCCAM become the
National Center for Complementary and Integrative




Precautions Interactions Side effects
St John’s
Wort
Increased sensitivity to sunlight Antidepressants
Birth control pills
Cyclosporin, which prevents the body
from rejecting transplanted organs
Digoxin, a heart medication
Some HIV drugs including indinavir
Some cancer medications including
irinotecan
Warfarin, an anticoagulant
Taking ST John’s Wort with certain
antidepressants or other drugs that affect
serotonin may lead to
increased serotonin-related side effects








Ginkgo If you are older, have a known bleeding risk,
or are pregnant you should be cautious about






Some evidence suggests that ginseng might affect
blood sugar and blood pressure. If you have diabetes
or high blood pressure consult your healthcare provider





Garlic Taking garlic may increase the risk of bleeding. If you take
an anticoagulant such as warfarin or if you need surgery
tell your healthcare provider if you’re taking or planning to
take garlic dietary supplements
Warfarin
Saquinavir (HIV)
Breath and body odour
Heartburn
Upset stomach
Some people have allergic
reactions to garlic
Echinacea Some people have allergic reactions which might be rare
People with atopy may be more likely to have an allergic
reaction when taking Echinacea
Digestive tract symptoms such
as nausea or stomach pain
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Health, or NCCIH. The ‘Herbs at a Glance’ section re-
mains and has been recently updated.
Data extraction and quality assurance
Data was extracted from the product container (and leaf-
let, if present) and entered into a Microsoft Excel database
according to pre-determined categories. Categories were
structured similarly to the Quality Review Document
product information template set out by the EMA. Data
was extracted by one researcher (RD) and an independent
10% check for accuracy was undertaken by another
(MCK).
Agreement on the key safety issues was undertaken as
a team (2 pharmacists and 2 nurses agreed the final
evaluation criteria as developed from NCCIH). These
were tabulated and the original packaging searched for
completeness and accuracy. Another 10% check for ac-
curacy was undertaken (MCK).
Results
Nature of the products
We found 67 products at 8 different retailers: 21 garlic,
9 St John’s wort, 17 echinacea, 10 Ginkgo biloba and 10
Asian ginseng.
Regulatory category
39.7% (n = 25) of the products were THR registered, this
demonstrates a large increase in the number of licenced
products available on the market, from the situation in
2011 when just 7% of the herbal products (n = 5) were
licensed (Chi2 = 19.4; df = 1; p = 0.000011)
One echinacea product did not have evidence of THR
registration on its packaging. However it is registered
under the scheme. It is possible this is old stock, how-
ever for the purposes of the study it have been classed as
OTHER n = 1 [1.6%].
Information provided
43% (n = 27) of the sample included a leaflet, although
the content of two of these largely consisted of promo-
tional materials, rather than information related to the
product’s safe and effective use. Registration with the
THR registration scheme was associated with an in-
creased likelihood of the presence of a leaflet. Only one
product registered under the THR scheme did not in-
clude a leaflet. Registered products were more likely to
be provided with a leaflet (Chi2 = 51.4; df - 1; p < .0001).
This represents an increase in the number of products
accompanied by a leaflet since the 2011 survey: from 7%
in 2011 to 43% in 2016 (Chi2 = 22.3; df = 1; p = 0.000002).
Key points of safety information
Tables 2,3,4,5 and 6 show each product, where it was
purchased, its licensed usage, and the number of key
points of safety information included with the product.
We found that both Echinacea and St John’s wort con-
sistently reported some of the key points of safety infor-
mation. For example, for St John’s wort we identified 16
key points of safety information (2 points of information
relating to precautions, 7 to interactions and 5 for side
effects). All the St John’s wort products we identified
communicated information about 14 out of the 16 key
points of safety information.
The remaining products, garlic, gingko and Asian gin-
seng, included examples of products which did not com-
municate any key points of safety information. For
example, for garlic we identified 8 key points of informa-
tion (2 points of information relating to precautions, 2
to interactions and 4 to side effects). We found 21 garlic
products, 4 of these communicated 1 out of 4 of the key
points of safety information and 17 did not contain any
of the key points of information.
Table 7 shows the presence or absence of information
points for each category of herbal product. In contrast
to the 2011 sample, where 75% (n = 51) of the sample
contained none of the key safety information the 2017
survey demonstrates a large decrease in the products
without key safety messages, key safety messages were
now included with 68% (n = 43) of the products (Chi2 =
24.6; df = 1; p < 0.000001). All of the products purchased
in 2017 with a THR registration contained at least some
of the key safety messages compared to around half of
the products without a THR (46%, n = 17).
Table 2 St John’s wort
Herbal product: SJW 7 8 19 20 45 46 47 58 67
Bought from Ph Ph HF HF Ph Ph Ph SM SM
Legal category THR THR THR THR THR THR THR THR THR
Leaflet supplied Yes Yes Yes Yes Yes Yes Yes Yes Yes
Precautions 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2
Interactions 7/7 7/7 7/7 7/7 7/7 7/7 7/7 7/7 7/7
Side effects 5/7 5/7 5/7 5/7 5/7 5/7 5/7 5/7 5/7
TOTAL XX/16 14/16 14/16 14/16 14/16 14/16 14/16 14/16 14/16 14/16
Ph pharmacy, HF health food store, SM supermarket, THR Traditional Herbal Registration, U unregulated, O other
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Risk of harm information
In PILs for regulated medicines, the risk of harm, or side
effect, information is typically presented using both ver-
bal and numerical frequency descriptors [14]. The
MHRA recommends that verbal descriptors of risk
should be accompanied by corresponding frequency in-
formation (e.g. “Common (affects less than 1 in 10
people)”). We also evaluated provision of such recom-
mended side effect frequency information, comparing
the 2011 and 2017 samples, to examine the extent to
which herbal products contain information about risk of
harm.
For all products, from both 2011 and 2017, risk of
harm information was only presented in the context of a
patient information leaflet. In 2011 we identified 68
products, 9 of which had product leaflets. Of these nine
leaflets, two used a combined format of verbal descrip-
tors and frequency bands. The two leaflets both included
the following information:
“Uncommon side-effects (affecting fewer than 1 in 100
people)” and “Other rarer side-effects….” (St. John’s
wort, Karma & Boots)
In 2017 there was an increase in the number of prod-
ucts with accompanying leaflets – 26 out of 63 com-
pared to 9 out of 67 in 2011. We identified that no
frequency information was included with products with-
out PILs.
We identified more leaflets reporting frequency infor-
mation, but this was not statistically significant. In 2017,
15 out of 26 leaflets presented some information of the
frequency associated with side effects. This compared to
2 out of 9 leaflets identified in the 2011 sample (Chi2 =
3.4; df = 1; p = 0.066).
A common approach, in 2017, to reporting frequency
information was for PILS to make reference to the fre-
quency associated with risk of harm by stating that the
frequency of side effects is not known. See example
below:
“The frequency is not known... This means it is not
known how often these reactions occur as there has not
been enough reports to allow this information to be
calculated.” Echinacea forte, A Vogel, Boots.
Discussion
The introduction of the THR scheme for herbal prod-
ucts appears to be associated with an increase in the
quality of information provided with herbal products. At
least 68% of the products sampled in the updated survey
contained some of the points of key information pertin-
ent to the safe use of the product. This compares to
2011 where only a quarter of products contained this in-
formation [8].
Our findings also report a significant increase in the
number of products registered with the THR scheme, al-
though in 2017 this still represents a minority. As the
registration scheme is associated with an increased fre-
quency of information about key safety points then this
is a positive move – consumers should be reassured that
the THR registered products are usually accompanied
with improved and more complete information than
those not registered.
For patients to make informed decisions about treat-
ments it is essential that there is full disclosure of any
key safety issues associated with taking an herbal medi-
cine. Some herbal products are associated with signifi-
cant drug interactions and side effects [5, 15]. St John’s
wort, for example, has a long documented interaction
Table 3 Ginkgo
Herbal product: Ginkgo 1 31 32 33 34 35 36 48 51 57
Bought from Ph HF HF HF HF HF HF Ph SM SM
Legal category U U U U U U U U U U
Leaflet supplied No No No No No No No No No No
Precautions 1/3 1/3 0/3 0/3 1/3 1/3 1/3 1/3 1/3 1/3
Interactions 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
Side effects 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
TOTAL: XX/7 1/7 1/7 0/7 0/7 1/7 1/7 1/7 1/7 1/7 1/7
Ph pharmacy, HF health food store, SM supermarket, THR Traditional Herbal Registration, U unregulated, O other
Table 4 Asian ginseng
Herbal product: Asian ginseng 4 21 49 52 60 62
Bought from Ph HF Ph SM SM HF
Legal category U U U U U U
Leaflet supplied No No No No No No
Precautions 3/3 0/3 1/3 1/3 1/3 1/3
Interactions 0/1 0/1 1/1 0/1 0/1 0/1
Side effects 0/3 0/3 0/3 0/3 0/3 0/3
TOTAL: XX/7 3/7 0/7 3/7 1/7 1/7 1/7
Ph pharmacy, HF health food store, SM supermarket, THR Traditional Herbal
Registration, U unregulated, O other
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with cyclosporine, a drug used to prevent organ rejec-
tion after transplant [16, 17]. However, our previous
study demonstrated that 27% of the St John’s wort prod-
ucts contained no points of key safety information [12].
The recent findings reported here demonstrate that
there has been a significant improvement with all the
sampled St John’s wort products containing at least
some of the key safety information identified.
There are a number of St John’s wort and echinacea
products which are registered as THRs, others, such as
garlic, may be regarded to be within the definition of a
medicine, but may also be available as food supplements.
Our findings show that registered medicinal products
are also more likely to be provided with key safety infor-
mation, compared to products lacking compulsory regis-
tration. Consumers and healthcare professionals should
be made aware of the THR licencing scheme and its as-
sociation with the increased provision of safety
information.
We found one product which was an exception; our
sample contained 1 echinacea product which was not
THR registered. It is possible that this is old stock, how-
ever as the transition period ended in 2011 it is likely to
be an unlicensed medicine. It is concerning that prod-
ucts without the required licence are available for pur-
chase over the counter. This was an issue we raised in
our 2011 paper and is something that continues to need
addressing. We are advised by MHRA that, where com-
plaints are received regarding the sale of borderline me-
dicinal products, they will review products case by case
and take appropriate action to remove products that fall
within the definition of a medicines from sale [18–20].
There also remains the issue of online availability of
products from suppliers outside the jurisdiction of the
MHRA [12]; consumers need to receive current infor-
mation which supports informed and safe use however
and wherever they buy a product [21, 22].
Our findings report an increase in the use of
MHRA-approved risk descriptors. However, despite an
increased willingness to present information about the
risks associated with medicines, the incidences of many
side effects are not known. This may reflect that such
events are rare, generated by isolated reports, or where
the absolute risk rate is not known or cannot be quanti-
fied, due to a lack of randomised controlled trials of suf-
ficient size.
There is evidence that people tend not to report ad-
verse effects of herbal medicines, or they report them
differently to conventional medicines [23, 24]. This also
has an impact on pharmacovigilance as accurate reports
of side effects and/or drug interactions might not be re-
ported in the first place, and consequently not included
in patient information leaflets, which are dependent on
post-licencing reporting. Both factors impact on the
availability of accurate frequency information about side
effects.
It is also widely acknowledged that there is a lack of
research data on the safety and effectiveness of herbal
medicines which also results in challenges in effectively
communicating the risk of harm to patients. The WHO
Table 5 Echinacea
Herbal product: Echinacea 5 6 25 26 27 28 29 30 42 43 44 53 54 56 61 65 66
Bought from Ph Ph HF HF HF HF HF HF Ph Ph Ph SM SM SM SM HF Ph
Legal category THR THR THR THR O THR THR THR THR THR THR THR THR THR THR THR THR
Leaflet supplied Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
Precautions 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 2/2 1/2 2/2
Interactions 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
Side effects 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
TOTAL: X/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 2/3 1/3 2/3
Ph pharmacy, HF health food store, SM supermarket, THR Traditional Herbal Registration, U unregulated, O other
Table 6 Garlic
Herbal product: Garlic 2 3 9 10 11 12 13 14 15 16 17 18 37 38 39 40 41 50 55 59 64
Bought from Ph Ph HF HF HF HF HF HF HF HF HF HF Ph Ph Ph Ph Ph SM SM SM HF
Legal category U U U U U U U U U U U U U U U U U U U U U
Leaflet supplied No No No No No No No No No No No Yes No No No No Yes No No No No
Precautions 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
Interactions 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 1/2 1/2 1/2 0/2 0/2 0/2 0/2 0/2 0/2
Side effects 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4
TOTAL: XX/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 0/8 1/8 1/8 1/8 1/8 0/8 0/8 0/8 0/8 0/8
Ph pharmacy, HF health food store, SM supermarket, THR Traditional Herbal Registration, U unregulated, O other
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acknowledges that despite a growing interest in Trad-
itional and Chinese medicines (under which herbal med-
icines are included), there are still many questions about
the quality and quantity of evidence to support their use
[9]. Indeed, the THR registration scheme does not evalu-
ate the effectiveness of herbal products; it states “No
clinical tests and trials on safety and efficacy are required
as long as sufficient safety data and plausible efficacy are
demonstrated” [25]. Products registered with the THR
scheme must have been used for at least 30 years, in-
cluding at least 15 years in the EU, however there is no
requirement for the product to have proven clinical ef-
fectiveness prior to registration. Despite the introduction
of the THR scheme, which has signified an increase in
the quality of information provided to consumers, there
remains an information deficit for consumers as a conse-
quence of a lack of clinical data reporting the effective-
ness of herbal products.
Strengths and limitations
We used an updated version of the NCCIH herbal
monographs in an attempt to replicate methods from
the previous study, although we acknowledge that the
use of different resource might have impacted on the
evaluation. The criteria generated from the NCCIH
monographs were not exhaustive, for example a key
safety issue associated with Echinacea is “Digestive tract
symptoms such as nausea or stomach pain” [26]. How-
ever the leaflets provided with Echinacea did not contain
details about this particular side effect, but they did con-
tain very detailed information on the possibility of auto-
immune conditions as a side effect [27], something not
highlighted by the National Center for Complementary
and Integrative Health. This detail was not captured in
our analysis.
We sampled a relatively small number of herbal prod-
ucts, and so the information provided with them might
not be typical of the sector. Similarly the statistical ana-
lysis of the change in provision between 2011 and 2017
is based on small numbers, and so is vulnerable to sam-
pling variation. We acknowledge our sample did not
include products such as creams, liquids and tinctures
and our findings may not be applicable to these
products.
We also acknowledge that the presence of information
does not assure that it is effectively communicated to
patients, for which a close textual analysis would be
required.
Conclusion
There has been a large increase in the availability of key
safety information provided with herbal products in the
UK over the period 2011–2017, which may be attribut-
able to the introduction of the THR scheme. However,
many herbal products are not included in the THR
scheme and at least half of those do not contain any in-
formation about safe use (such as about precautions, in-
teractions and side effects). The public needs to be
better informed about ways to optimise safe use of all
herbal products. As products with registered with the
THR scheme have been assessed for quality, safety and
traditional use, healthcare professionals could optimise
safe use of herbal products by advising on the availability
of THR products.
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Table 7 Presence or absence of information points for each
category of herbal product




Echinacea, n = 17 (%) 17 (100%) 0 (0%)
St John’s Wort, n = 9 (%) 9 (100%) 0 (0%)
Garlic, n = 21 (%) 4 (19%) 17 (81%)
Gingko, n = 10 (%) 8 (80%) 2 (20%)
Asian ginseng, n = 6 (%) 5 (84%) 1 (16%)
Total, n = 63 (%) 43 (68%) 20 (32%)
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